Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy.

Literature DB >> 29593340

Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy.

Jonathan Pol^1,2,3,4, Guido Kroemer^5,6,7,8,9,10.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2018 PMID： 29593340 PMCID： PMC5951874 DOI： 10.1038/s41422-018-0031-9

Source DB: PubMed Journal: Cell Res ISSN： 1001-0602 Impact factor: 25.617

× No keyword cloud information.

12 in total

Review 1. Coinhibitory Pathways in Immunotherapy for Cancer.

Authors: Susanne H Baumeister; Gordon J Freeman; Glenn Dranoff; Arlene H Sharpe
Journal: Annu Rev Immunol Date: 2016-02-25 Impact factor: 28.527

2. Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.

Authors: Udupi A Ramagopal; Weifeng Liu; Sarah C Garrett-Thomson; Jeffrey B Bonanno; Qingrong Yan; Mohan Srinivasan; Susan C Wong; Alasdair Bell; Shilpa Mankikar; Vangipuram S Rangan; Shrikant Deshpande; Alan J Korman; Steven C Almo
Journal: Proc Natl Acad Sci U S A Date: 2017-05-08 Impact factor: 11.205

Review 3. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

Authors: Padmanee Sharma; James P Allison
Journal: Cell Date: 2015-04-09 Impact factor: 41.582

4. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.

Authors: Mark J Selby; John J Engelhardt; Michael Quigley; Karla A Henning; Timothy Chen; Mohan Srinivasan; Alan J Korman
Journal: Cancer Immunol Res Date: 2013-04-07 Impact factor: 11.151

5. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.

Authors: Emanuela Romano; Monika Kusio-Kobialka; Periklis G Foukas; Petra Baumgaertner; Christiane Meyer; Pierluigi Ballabeni; Olivier Michielin; Benjamin Weide; Pedro Romero; Daniel E Speiser
Journal: Proc Natl Acad Sci U S A Date: 2015-04-27 Impact factor: 11.205

Review 6. Ipilimumab and its toxicities: a multidisciplinary approach.

Authors: Leslie A Fecher; Sanjiv S Agarwala; F Stephen Hodi; Jeffrey S Weber
Journal: Oncologist Date: 2013-06-17

7. Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice.

Authors: Xuexiang Du; Mingyue Liu; Juanjuan Su; Peng Zhang; Fei Tang; Peiying Ye; Martin Devenport; Xu Wang; Yan Zhang; Yang Liu; Pan Zheng
Journal: Cell Res Date: 2018-02-20 Impact factor: 25.617

Review 8. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer.

Authors: James D Mellor; Michael P Brown; Helen R Irving; John R Zalcberg; Alexander Dobrovic
Journal: J Hematol Oncol Date: 2013-01-04 Impact factor: 17.388

9. Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.

Authors: Yannick Bulliard; Rose Jolicoeur; Maurice Windman; Sarah M Rue; Seth Ettenberg; Deborah A Knee; Nicholas S Wilson; Glenn Dranoff; Jennifer L Brogdon
Journal: J Exp Med Date: 2013-07-29 Impact factor: 14.307

10. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.

Authors: Xuexiang Du; Fei Tang; Mingyue Liu; Juanjuan Su; Yan Zhang; Wei Wu; Martin Devenport; Christopher A Lazarski; Peng Zhang; Xu Wang; Peiying Ye; Changyu Wang; Eugene Hwang; Tinghui Zhu; Ting Xu; Pan Zheng; Yang Liu
Journal: Cell Res Date: 2018-02-22 Impact factor: 25.617

7 in total

7. Comprehensive Analysis of Innate Immunophenotyping Based on Immune Score Predicting Immune Alterations and Prognosis in Breast Cancer Patients.

Authors: Weiguang Liu; Lingling Xia; Zhengmiao Xia; Liming Chen
Journal: Genes (Basel) Date: 2021-12-29 Impact factor: 4.096

7 in total

Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy.

Review 1. Coinhibitory Pathways in Immunotherapy for Cancer.

2. Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.

Review 3. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

4. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.

5. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.

Review 6. Ipilimumab and its toxicities: a multidisciplinary approach.

7. Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice.

Review 8. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer.

9. Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.

10. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.

Review 1. Development of bispecific antibodies in China: overview and prospects.

Review 2. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response.

3. Development of a structure-based computational simulation to optimize the blocking efficacy of pro-antibodies.

Review 4. Single-Cell Approaches to Profile the Response to Immune Checkpoint Inhibitors.

Review 5. Immunotherapies and Combination Strategies for Immuno-Oncology.

Review 6. A Hot Topic: Cancer Immunotherapy and Natural Killer Cells.

7. Comprehensive Analysis of Innate Immunophenotyping Based on Immune Score Predicting Immune Alterations and Prognosis in Breast Cancer Patients.